Clinical Report: Addressing Challenges in Pediatric Oncology Rehabilitation
Overview
This study highlights significant gaps in rehabilitation accessibility for pediatric oncology patients, with 63.7% of parents reporting a need for rehabilitation during treatment, yet only 53.3% receiving it.
Background
Rehabilitation is essential for improving the quality of life in pediatric oncology patients, particularly as many survivors experience chronic health conditions post-treatment. Despite the known benefits of rehabilitation, barriers hinder its effective implementation in clinical practice.
Data Highlights
Finding
Percentage
Parents reporting need for rehabilitation during treatment
63.7%
Children receiving rehabilitation during treatment
53.3%
Unmet need rate post-treatment
13.3%
Children requiring therapy for more than six months during treatment
29.5%
Children requiring therapy post-treatment
47.6%
Physiotherapists rating their knowledge as insufficient
80%
Rehabilitation physicians rating their knowledge as insufficient
74%
Key Findings
63.7% of parents reported their child required rehabilitation during active treatment.
Only 53.3% of children received the rehabilitation they needed during treatment.
The unmet need rate for rehabilitation rose to 13.3% after treatment completion.
29.5% of children required therapy for more than six months during treatment, increasing to 47.6% post-treatment.
80% of physiotherapists and 74% of rehabilitation physicians felt their graduation-level knowledge was insufficient.
66% of physiotherapists and 54% of physicians expressed interest in joining a specialized competence network.
Clinical Implications
The findings indicate a need for targeted educational programs to enhance the knowledge and skills of rehabilitation providers in pediatric oncology. Establishing a structured competence network may facilitate better access to rehabilitation services for children with cancer.
Conclusion
The study reveals a significant gap between the demand for rehabilitation services and the capacity of the healthcare system to provide them.
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
